Sheffield-headquartered Rinri Therapeutics, a biotechnology company developing a novel cell-based therapy to restore hearing, has appointed a new chief technology officer.
Dr Terri Gaskell brings more than 20 years of life sciences R&D experience in both academic and industry roles with a focus on the development and translation of cell and gene-based therapies.
Gaskell joins from the UK Cell and Gene Therapy Catapult (CGTC) where she has worked for more than seven years on the translation of a broad range of candidate therapies, including stem cell derived, alongside underpinning technologies and infrastructure.
Her role at CGTC also included advising academics and small companies on the development of advanced therapies.
She said: “I look forward to using my experience in translation of candidate cell therapies to help advance this promising and innovative therapy to the clinic and ultimately achieve the ambition of improving the lives of patients with hearing loss.”
Dr Simon Chandler, CEO of Rinri, added: “Terri is a very talented technical operations executive who brings to Rinri deep and broad experience that spans across regulatory, process development and clinical trial design.
“We are excited to add such a talent to our executive team and look forward to her applying her knowledge to help us accelerate the development of our pioneering technology to reverse sensorineural hearing loss.”